Table 3.
Univariate and multivariate analysis of overall survival with second-line chemotherapy
| Univariate analysis |
Multivariate analysis |
|||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Sex | ||||
| Male | Reference | - | - | |
| Female | 0.94 (0.63-1.41) | 0.77 | - | - |
| Initial disease status | ||||
| Recurrent | Reference | - | - | |
| Metastatic | 1.09 (0.70-1.69) | 0.70 | - | - |
| Age (yr) | ||||
| ≤ 60 | Reference | - | - | |
| > 60 | 0.88 (0.59-1.31) | 0.52 | - | - |
| ECOG performance status | ||||
| 0 | Reference | - | - | |
| 1-2 | 1.46 (0.96-2.20) | 0.08 | - | - |
| CA19-9 | ||||
| Normal | Reference | - | - | |
| Elevated | 1.12 (0.63-1.99) | 0.70 | - | - |
| Albumin | ||||
| Normal | Reference | - | - | |
| Decreased | 1.16 (0.78-1.73) | 0.46 | - | - |
| NLR | ||||
| ≤ 2.2 | Reference | Reference | ||
| > 2.2 | 1.78 (1.19-2.66) | < 0.01 | 1.58 (1.05-2.38) | 0.03 |
| PLR | ||||
| ≤ 154.4 | Reference | - | - | |
| > 154.4 | 1.57 (1.05-2.36) | 0.03 | - | - |
| No. of metastatic sites | ||||
| 0-1 | Reference | Reference | ||
| ≥ 2 | 1.60 (1.07-2.38) | 0.02 | 1.48 (0.99-2.22) | 0.06 |
| Presence of liver metastasis | ||||
| No | Reference | - | - | |
| Yes | 1.77 (1.16-2.69) | < 0.01 | - | - |
| Presence of lung metastasis | ||||
| No | Reference | - | - | |
| Yes | 0.97 (0.62-1.52) | 0.88 | - | - |
| Presence of bone metastasis | ||||
| No | Reference | - | - | |
| Yes | 2.05 (0.943-4.44) | 0.07 | - | - |
| Presence of peritoneal metastasis | ||||
| No | Reference | - | - | |
| Yes | 0.99 (0.66-1.49) | 0.95 | - | - |
| Presence of lymph nodes metastasis | ||||
| No | Reference | - | - | |
| Yes | 1.15 (0.76-1.73) | 0.51 | - | - |
| 1L-TTP (mo) | ||||
| ≤ 6.4 | 1.68 (1.13-2.52) | 0.01 | 1.57 (1.05-2.36) | 0.03 |
| > 6.4 | Reference | Reference | ||
| Best response for first-line nab-P+GEM | ||||
| CR/PR/SD | Reference | - | - | |
| PD | 1.38 (0.83-2.31) | 0.22 | - | - |
| Second-line regimen | ||||
| Fluoropyrimidine monotherapy | Reference | - | - | |
| Fluoropyrimidine-oxaliplatin doublets | 0.96 (0.62-1.50) | 0.86 | - | - |
HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; CA19-9, carbohydrate antigen 19-9; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; 1L, first line; TTP, time to progression; nab-P+GEM, nab-paclitaxel plus gemcitabine; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.